Cincinnati Children’s Hospital announced today that a preclinical trial of a targeted molecular therapy has shown success in shrinking formerly untreatable NF1 tumors. Please click here to read more about this encouraging advancement in NF research.
“We can for the first time shrink the large majority of neurofibromas, at least in mice, by using a molecularly targeted treatment,” said Nancy Ratner, PhD, principal investigator and program leader for the Cancer Biology and Neural Tumors Program in the Cancer and Blood Disorders Institute at Cincinnati Children’s. “At present there is no treatment for these tumors and our data provide strong rationale for testing this therapy in clinical trials for NF1.”
Cincinnati Children’s Hospital has been a member of our NF Preclinical Consortium since 2008, and we are proud to have played a part in funding this important work.
